Stay updated with breaking news from Nasdaq Cbay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) had its price objective raised by Cantor Fitzgerald from $13.00 to $15.00 in a report issued on Tuesday morning, The Fly reports. Cantor Fitzgerald also issued estimates for CymaBay Therapeutics’ FY2023 earnings at ($1.15) EPS. A number of other research analysts have also issued reports on CBAY. Raymond James […]
StockNews.com cut shares of CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) from a hold rating to a sell rating in a research note published on Monday. CBAY has been the topic of several other research reports. SVB Leerink boosted their target price on shares of CymaBay Therapeutics from $10.00 to $12.00 and gave the stock an […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) General Counsel Paul T. Quinlan sold 5,000 shares of CymaBay Therapeutics stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $10.37, for a total value of $51,850.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) – Analysts at HC Wainwright lifted their Q2 2023 earnings per share estimates for CymaBay Therapeutics in a report released on Tuesday, May 16th. HC Wainwright analyst E. Arce now anticipates that the biopharmaceutical company will post earnings per share of $0.04 for the quarter, up from their […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) saw a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 11,070,000 shares, a growth of 7.3% from the April 15th total of 10,320,000 shares. Based on an average daily volume of 1,640,000 shares, the days-to-cover ratio is […]